Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
NEW YORK, Nov. 16 Personalized Pharmaceutical Systems (PPS) today announced the sale of the Angioedema Clinical Prediction Guide to Viropharma Incorporated.
PPS is a clinical trial enrichment and market differentiation company which has developed advanced technology in phenomics to help drug companies identify the correct patients for their drugs, and as a result help patients get the right drug the first time. Through the use of its phenomic technology, PPS developed the Angioedema Clinical Prediction Guide to help emergency room physicians quickly differentiate amongst different types of angioedema (AE) that can be life-threatening.
Allergic angioedema is more common, and can be treated with antihistaminergic treatments. Hereditary Angioedema (HAE) is a rare form of AE seen in less than 1% of AE patients presenting to emergency rooms, and is not treatable with antihistaminergic treatments. Due to both the rareness of HAE and the complexity of differentiating amongst the various types of AE, the HAE patient is often misdiagnosed and treated inappropriately in the emergency room, increasing the risk of life-threatening airway compromise.
Correct diagnosis of HAE is known to take, on average, several years from a patient's first visit to an emergency room. Viropharma has licensed the Angioedema Clinical Prediction Guide and is currently considering a large-scale retrospective validation analysis. If validated, Viropharma may use the Angioedema Clinical Prediction Guide as a component of their medical education strategy to give physicians a means to recognize rarer forms of AE, and thereby accelerate the referral and diagnosis of HAE.
"We are extremely pleased with this opportunity for Viropharma to use our technology to accelerate the diagnosis of patients with this very severe disease. We look forward to the possibility of future collaboration and new opportunities to optimize Viropharma's clinical trial design, increase physician awareness, and maximize patient access," Dr. Paul Herscu, CEO, PPS.
About Personalized Pharmaceutical Systems LLC
Personalized Pharmaceutical Systems (PPS) is a cutting edge clinical trial enhancement and market differentiation company designed to dramatically reduce risk for pharmaceutical companies in both drug development and post-market entry phases. PPS novel enrichment technology utilizes inter-individual variability, that currently confounds drug trials, to enhance efficacy outcomes and/or significantly reduce risk of adverse effects. PPS technology effectively dissects diagnostic populations into treatment response correlated subgroups through the analysis of thousands of clinical indices measured against a continuum of environmental variables. While most clinical trials currently compare 40-50 clinical indices against clinical outcomes, PPS templates consider over 1000 indices mapped against a continuum of environmental variations and tested in thousands of patients over the past 15 years. This level of granularity brings a new level of precision to provide reliable determination of true clinical phenotype at the whole patient level. This technology creates new opportunity for success with compounds that are stalled or failing in current trials. PPS technology can be seamlessly incorporated into existing Phase II-IV trials.
SOURCE Personalized Pharmaceutical Systems
You May Also Like